BIO 300

Drug Profile

BIO 300

Alternative Names: BIO-300

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Armed Forces Radiobiology Research Institute; National Institutes of Health (USA)
  • Developer Henry Ford Health System; Humanetics Corporation
  • Class Radioprotectives
  • Mechanism of Action Antioxidants; Apoptosis inhibitors; Haematopoietic cell growth factor stimulants; Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute radiation syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Radiation injuries
  • No development reported Acute radiation syndrome

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Acute-radiation-syndrome(Prevention, In volunteers) in USA (PO, Capsule)
  • 01 Nov 2015 Phase-I/II clinical trials in Radiation injuries (Prevention) (in patients with non-small cell lung cancer) in USA (PO)
  • 02 Jun 2015 The US FDA approves IND application for BIO 300 in Radioprotection (in non-small cell lung cancer)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top